Regulation fixes or caps the price of one slice of a pharmacy's range, usually reimbursed prescription medicines. Everything else, over-the-counter medicines, self-care, dermocosmetics, infant nutrition, devices, supplements and delivery, is priced by you. In most community pharmacies that free-priced remainder carries the larger share of gross profit.
So the floor is not the constraint it gets described as. The constraint is assuming the floor covers more of the range than it does, and then never making a real decision about the part that is open.
The regulated slice still needs watching, for a reason that has nothing to do with its price: products move in and out of it.
Four shapes of pharmacy price regulation
Markets in Europe, the Gulf and North America use one of four structures, often several at once for different parts of the range.
- Fixed price: one lawful retail price, no discount and no premium, typically built as a defined margin plus a per-pack fee on top of the manufacturer's price
- Maximum price: a published ceiling that you are permitted to sell below
- Reference reimbursement: the payer covers up to a reference amount and the patient pays any difference, so your price is free but demand is very sensitive around the reference point
- Free price: no rule beyond general consumer and advertising law
Which structure applies to which product is a question for your national list, and the answer changes. The commercially interesting cases are the last three. A maximum price in particular is a decision dressed as a rule: most pharmacies sell at the ceiling and treat it as fixed, which is a choice nobody remembers making.
The regulated list is not static
The highest-value thing to monitor in a regulated market is not the price of a fixed-price product. It is the moment a product stops being one.
- A prescription-only medicine switching to over-the-counter status, at which point the price becomes free overnight
- Loss of reimbursement, or removal from a payer's list
- First generic entry, which moves an entire reference group
- A new pack size or strength, which gets a new article code and carries no pricing history
- A supply shortage, which changes what is actually orderable and what a competitor can honour
On the day one of those events lands, nobody in the market has set a price on purpose. That is the window where a considered decision is worth the most, and it closes within weeks as everyone copies the first mover.
Match on the article code, not the product name
Every European pharmacy market has a national article code: PZN in Germany and Austria, CIP in France, PIP in the United Kingdom, Código Nacional in Spain, with equivalents elsewhere. One code means one manufacturer, one strength, one pack size, one presentation.
Name matching fails on precisely the attributes that set the price. Strength and count sit in the title as loose text, sometimes as 400mg, sometimes as 400 mg, sometimes only in the pack shot. A tool that matches on titles will pair a 20-tablet pack with a 50 and report a price gap that does not exist.
Where a competitor publishes the code, use it as the primary key and keep the title only as a check against code reuse and data entry errors.
Pack size is where the arithmetic hides
Take ibuprofen 400 milligrams. A 20-tablet pack at 4.95 is 4.95 / 20 = 0.2475 per tablet. A 50-tablet pack at 9.45 is 9.45 / 50 = 0.189 per tablet. The larger pack is about 24 percent cheaper per tablet, since 0.189 / 0.2475 = 0.76, while carrying nearly twice the cash margin.
An engine that treats those two as one product reports that you are 91 percent too expensive, because 9.45 / 4.95 = 1.91. Somebody then cuts a price that was correct.
Per-unit normalisation is genuinely useful in pharmacy in a way it is not in wine, because a tablet is a tablet. Normalise per tablet, per millilitre or per application for analysis, but compare like pack sizes when you set the shelf price, because that is what the customer is choosing between.
What an over-the-counter discount actually costs
Take a self-care line selling at 9.95 with a cost of 6.00. Gross profit is 3.95 a unit, a gross margin of 3.95 / 9.95 = 39.7 percent.
Cut the shelf price to 8.95 and gross profit falls to 2.95. To hold the same total gross profit you now need 3.95 / 2.95 = 1.34, so 34 percent more units. A one euro cut, close to 10 percent off the shelf price, requires a third more volume just to stand still.
Few pharmacy categories have that elasticity outside a small set of price-visible lines. This arithmetic is why most pricing errors in pharmacy retail are prices set too low rather than too high: the cost of the cut is immediate and certain, and the volume response is hoped for.
What competitor monitoring is actually for here
- Detecting the day a product leaves the regulated bucket, before the market settles into a habit
- Finding the small number of price-visible lines where you sit visibly above a nearby competitor, since those lines carry the store's price image
- Finding the much larger set where you sit below the market and nobody has noticed
- Watching mail-order and platform prices, which set the reference a customer quotes at the counter even when they buy from you
- Tracking delivery fees, thresholds and click-and-collect terms, which are prices even though they do not sit on a product
- Catching your own errors: a misplaced decimal appears as an outlier against the market days before it appears in the till
What is still yours to decide
Under a fixed price, the price of that pack is not a decision. Almost everything around it still is.
- Assortment depth, and which own-brand lines sit beside the branded ones
- Pack size mix, which moves the average basket without changing a single shelf price
- Whether to sell below a maximum price, on which lines, and for how long
- Delivery and service pricing, including whether a service is free, bundled or charged
- Which lines carry your price image and deserve a weekly check, against the long tail that deserves a monthly one
A monitoring tool, PriceRoom or another, is only useful here if it holds the article code as the identity and the regulatory status as a field that changes over time. Without the second, you learn that a product went free-priced from a competitor's margin, which is late.